Arteriotomy Closure Devices Market By Product Type (Passive Closure Devices, Active Closure Devices, External Compression Devices); By Access Site (Femoral, Radial, Others); By End User (Hospitals, ASCs, Cath Labs, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Arteriotomy Closure Devices Market is projected to expand at a 7.4% CAGR, rising from $1.21 billion in 2024 to $1.86 billion by 2030, supported by vascular closure devices, minimally invasive surgery, interventional cardiology, angiography, cardiac catheterization, and endovascular procedures, notes Strategic Market Research.

 

Arteriotomy closure devices (ACDs) are medical tools designed to achieve rapid and secure hemostasis following arterial puncture during endovascular procedures, such as coronary angiography and peripheral interventions. These devices reduce time-to-ambulation, minimize complications like hematoma or pseudoaneurysm, and enhance patient throughput — a significant operational benefit in today’s high-volume cardiovascular suites.

 

From a strategic healthcare standpoint, the demand for ACDs is being propelled by three major macro forces:

• Rising Procedure Volumes : With the increasing global prevalence of cardiovascular diseases (CVDs), including coronary artery disease and peripheral artery disease, the number of catheter-based interventions has surged. This directly boosts the consumption of closure devices.

• Regulatory Pressure on Surgical Efficiency : Hospitals and outpatient facilities are under mounting pressure to reduce recovery times, minimize hospital stays, and improve procedural outcomes. ACDs contribute directly to these benchmarks.

• Technology-Driven Care Models : Innovations in minimally invasive and image-guided interventions have paved the way for more complex endovascular procedures to be done in ambulatory settings — increasing reliance on fast and reliable closure mechanisms.

 

Key stakeholders in this evolving ecosystem include:

• Medical device OEMs focusing on catheter-based innovations and access management.

• Hospitals and catheterization labs , especially those migrating toward same-day discharge models.

• Ambulatory surgical centers (ASCs) , now performing an increasing number of vascular procedures.

• Regulatory and reimbursement bodies , influencing procurement based on safety profiles and cost-effectiveness.

• Private equity firms and investors , increasingly funding start-ups working on next-gen vascular access solutions.

As the focus in cardiovascular care shifts from just procedural success to post-procedure recovery and efficiency, arteriotomy closure devices will continue to evolve from commodity tools into integral components of patient- centered vascular management.

 

Comprehensive Market Snapshot

• The Global Arteriotomy Closure Devices Market is projected to expand at a 7.4% CAGR, rising from USD 1.21 billion in 2024 to USD 1.86 billion by 2030.

• Based on a 40% share of the 2024 global market, the USA Arteriotomy Closure Devices Market is estimated at USD 0.48 billion in 2024, and at a 6.3% CAGR is projected to reach approximately USD 0.70 billion by 2030.

• With a 25% share, the Europe Arteriotomy Closure Devices Market is estimated at USD 0.30 billion in 2024, and at a 5.2% CAGR is expected to reach around USD 0.41 billion by 2030.

• With a 16% share, the APAC Arteriotomy Closure Devices Market is estimated at USD 0.19 billion in 2024, and at a 9.5% CAGR is projected to reach approximately USD 0.33 billion by 2030.

Regional Insights

• North America (USA) accounted for the largest market share of 40.0% in 2024, supported by high interventional cardiology volumes, early adoption of vascular closure technologies, and strong hospital infrastructure.

• Asia Pacific (APAC) is expected to expand at the fastest CAGR of 9.5% during 2024–2030, driven by rapid growth in catheterization labs, increasing cardiovascular disease burden, and improving access to minimally invasive procedures.

 

By Product Type

• Passive Closure Devices held the largest market share of 43.0% in 2024, reflecting widespread physician familiarity and cost-effective deployment across femoral access procedures.

• Active Closure Devices are projected to grow at a notable CAGR over 2024–2030, driven by faster hemostasis, reduced ambulation time, and increasing preference in complex interventions.

Estimated 2024 Market Split (Global)

• Passive Closure Devices held the largest market share of 43.0% in 2024, reflecting strong physician familiarity and cost-effective deployment across femoral access procedures, with an estimated market value of approximately USD 0.52 billion.

• Active Closure Devices accounted for an estimated 35.0% share in 2024, translating to approximately USD 0.42 billion, and are projected to grow at a notable CAGR during 2024–2030 due to faster hemostasis, reduced ambulation time, and rising use in complex interventions.

• External Compression Devices represented the remaining 22.0% of the global market in 2024, with an estimated value of approximately USD 0.27 billion, supported by continued use in low-risk and cost-sensitive procedures.

 

By Access Site

• Femoral Access accounted for the highest market share in 2024, owing to its continued dominance in structural heart and peripheral interventions.

• Radial Access is expected to grow at a strong CAGR during 2024–2030, supported by lower bleeding risk and rising adoption in coronary angiography.

Estimated 2024 Market Split (Global)

• Femoral Access accounted for the highest market share of 58.0% in 2024, driven by its continued dominance in structural heart and peripheral vascular interventions, with an estimated market size of approximately USD 0.70 billion.

• Radial Access represented 32.0% of the global market in 2024, equivalent to approximately USD 0.39 billion, and is expected to expand at a strong CAGR through 2030 due to lower bleeding risk and increasing adoption in coronary angiography.

• Others accounted for the remaining 10.0% share in 2024, translating to approximately USD 0.12 billion, reflecting limited but steady use in alternative access approaches.

 

By End User

• Hospitals contributed the largest share of the market in 2024, reflecting high procedural volumes and advanced interventional capabilities.

• Ambulatory Surgical Centers (ASCs) are anticipated to expand at a robust CAGR over the forecast period, driven by same-day discharge trends and cost containment initiatives.

Estimated 2024 Market Split (Global)

• Hospitals contributed the largest share of 46.0% in 2024, supported by high procedural volumes and advanced interventional capabilities, with an estimated market value of approximately USD 0.56 billion.

• Ambulatory Surgical Centers accounted for 24.0% of the market in 2024, corresponding to approximately USD 0.29 billion, and are anticipated to grow at a robust CAGR due to same-day discharge trends and cost-containment initiatives.

• Cath Labs represented 20.0% of the global market in 2024, with an estimated value of approximately USD 0.24 billion, driven by specialized diagnostic and interventional procedures.

• Specialty Clinics held the remaining 10.0% share in 2024, translating to approximately USD 0.12 billion, supported by outpatient vascular and follow-up care services.

 

By Treatment Setting

• Hospitals dominated the market with the largest share in 2024, driven by complex vascular procedures and inpatient interventional care.

• Telehealth Platforms are expected to witness accelerated growth during 2024–2030, primarily through post-procedure monitoring, follow-up consultations, and digital care pathways.

Estimated 2024 Market Split (Global)

• Hospitals dominated the treatment-setting segment with a 48.0% share in 2024, reflecting high utilization in complex vascular procedures and inpatient interventional care, with an estimated value of approximately USD 0.58 billion.

• Ambulatory Surgical Centers accounted for 27.0% of the market in 2024, equivalent to approximately USD 0.33 billion, driven by procedural efficiency and lower cost settings.

• Diagnostic Imaging Centers represented 15.0% of the global market in 2024, with an estimated value of approximately USD 0.18 billion, supported by imaging-guided vascular procedures.

• Telehealth Platforms accounted for 10.0% of the market in 2024, translating to approximately USD 0.12 billion, and are expected to experience accelerated growth during 2024–2030 through post-procedure monitoring and digital care pathways.

 

Strategic Questions Driving the Next Phase of the Global Arteriotomy Closure Devices Market

1. What device types, access sites, and clinical procedures are explicitly included within the Arteriotomy Closure Devices Market, and which vascular or hemostasis solutions are considered out of scope?

2. How does the Arteriotomy Closure Devices Market differ structurally from adjacent markets such as vascular access devices, compression systems, and hemostatic agents?

3. What is the current and forecasted size of the global Arteriotomy Closure Devices Market, and how is value distributed across major device categories?

4. How is revenue allocated between passive closure devices, active closure devices, and external compression systems, and how is this mix expected to evolve?

5. Which access-site segments (femoral, radial, and alternative access) account for the largest and fastest-growing revenue pools?

6. Which device segments contribute disproportionately to profit and margin generation rather than procedure volume alone?

7. How does demand vary between diagnostic, interventional, and complex structural heart or peripheral vascular procedures?

8. How are closure device preferences evolving across first-line standard procedures versus advanced or high-risk interventions?

9. What role do procedure volumes, repeat interventions, and device re-adoption rates play in segment-level revenue growth?

10. How are cardiovascular disease prevalence, interventional procedure growth, and catheterization lab expansion shaping global demand?

11. What clinical, anatomical, or complication-related factors limit the adoption of specific closure device technologies?

12. How do pricing pressure, hospital procurement practices, and reimbursement policies influence revenue realization across device segments?

13. How strong is the current and mid-term innovation pipeline, and which emerging closure mechanisms are likely to create new device categories?

14. To what extent will next-generation devices expand the treated procedure pool versus intensify competition within existing segments?

15. How are advances in materials, bioabsorbable components, and deployment mechanisms improving safety, efficacy, and ease of use?

16. How will patent expirations and technology commoditization reshape competitive dynamics across closure device categories?

17. What role will lower-cost alternatives and emerging-market manufacturers play in price erosion and access expansion?

18. How are leading manufacturers aligning product portfolios, physician training, and clinical evidence strategies to defend or grow market share?

19. Which geographic regions are expected to outperform global growth in the Arteriotomy Closure Devices Market, and which access-site or device segments are driving this outperformance?

20. How should device manufacturers and investors prioritize technologies, access sites, and regions to maximize long-term value creation?

 

Segment-Level Insights and Market Structure for Arteriotomy Closure Devices Market

The Arteriotomy Closure Devices Market is organized around distinct device technologies, access-site applications, and care delivery channels, each reflecting differences in procedural complexity, clinical risk, and post-intervention management. These segments contribute unevenly to overall market value, competitive positioning, and innovation momentum. Segment performance is shaped by procedural volume trends, physician preferences, patient recovery goals, and the increasing shift toward minimally invasive cardiovascular and endovascular interventions.

Product Type Insights:

Passive Closure Devices

Passive closure devices represent a widely utilized and well-established segment within the arteriotomy closure landscape. These devices rely on natural coagulation or mechanical compression mechanisms to achieve hemostasis following vascular access procedures. Their adoption is driven by familiarity, predictable performance, and suitability for routine diagnostic and interventional procedures. From a market standpoint, passive devices support high procedure throughput and remain a cornerstone in standard femoral access closures. Over time, their role is being refined as hospitals balance cost efficiency with evolving expectations for faster ambulation and reduced complication rates.

Active Closure Devices

Active closure devices constitute a more technology-driven segment, designed to achieve rapid and controlled vessel closure through sutures, clips, or bioabsorbable components. These systems are increasingly favored in complex interventions where faster hemostasis and early patient mobilization are prioritized. Commercially, active devices tend to command higher per-unit value due to their advanced design and clinical benefits. Their relevance is expanding as procedural complexity increases and healthcare providers focus on shortening recovery times and optimizing cath lab efficiency.

External Compression Devices

External compression devices occupy a complementary role within the market, providing non-invasive or semi-invasive hemostasis solutions. These devices are often used in settings where manual compression needs to be standardized or when closure devices are contraindicated. Although they generally represent a lower-technology segment, external compression systems contribute meaningfully to volume-driven demand, particularly in cost-sensitive environments. Their market role continues to evolve as workflow automation and staff efficiency become more prominent considerations in procedural care.

 

Access Site Insights:

Femoral Access

Femoral access remains the most established and widely supported access site for arteriotomy closure devices. Its continued use in structural heart procedures, peripheral interventions, and large-bore access cases underpins sustained demand for reliable closure solutions. From a segmentation perspective, femoral access accounts for a substantial portion of device utilization due to higher bleeding risk and the clinical necessity for effective vessel closure.

Radial Access

Radial access is an increasingly influential segment, reflecting a broader shift toward less invasive cardiovascular procedures. While radial interventions traditionally rely less on dedicated closure devices, growing procedure volumes and evolving techniques are creating new opportunities for radial-specific closure solutions. This segment is associated with favorable patient outcomes, including reduced bleeding complications and quicker recovery, which supports its long-term growth potential.

Other Access Sites

Other access sites, including alternative peripheral entry points, represent a smaller but clinically relevant segment. These procedures often require customized closure approaches due to anatomical variability or patient-specific considerations. Although limited in volume, this segment benefits from innovation aimed at addressing niche procedural needs and complex patient populations.

 

End User and Care Setting Insights;

Hospitals

Hospitals represent the primary end-user segment for arteriotomy closure devices, driven by high volumes of interventional cardiology, vascular surgery, and structural heart procedures. Their role is reinforced by the concentration of advanced imaging, specialized clinicians, and post-procedural monitoring capabilities. From a market perspective, hospitals account for the majority of high-value device utilization, particularly for active closure technologies used in complex cases.

Ambulatory Surgical Centers (ASCs)

Ambulatory surgical centers are emerging as an increasingly important care setting as procedures migrate toward outpatient models. ASCs prioritize efficiency, rapid patient turnover, and cost control, influencing device selection toward solutions that support same-day discharge. This segment is gaining strategic importance as healthcare systems seek to reduce inpatient burden while maintaining procedural safety.

Catheterization Laboratories

Standalone and hospital-affiliated catheterization laboratories form a distinct segment characterized by high procedural specialization. Device demand in this setting is closely tied to workflow optimization, complication avoidance, and physician preference. Cath labs often serve as early adopters of new closure technologies, particularly those that enhance procedural consistency and reduce recovery time.

Specialty Clinics

Specialty clinics represent a smaller but growing end-user segment, particularly for diagnostic or lower-complexity vascular procedures. Device utilization in these settings emphasizes ease of use, reliability, and cost-effectiveness. As procedural capabilities expand outside traditional hospital environments, specialty clinics are expected to contribute incrementally to overall market demand.

 

Segment Evolution Perspective

While traditional closure technologies continue to anchor current procedural practices, innovation-driven segments—particularly active closure devices and outpatient-focused care settings—are gradually reshaping the competitive landscape. At the same time, shifts toward minimally invasive access, faster recovery protocols, and decentralized care delivery are influencing how value is distributed across segments. Collectively, these dynamics are expected to redefine adoption patterns, pricing structures, and growth trajectories within the arteriotomy closure devices market over the coming years.

 

Table: Key Approved and Late-Stage Arteriotomy Closure Device Platforms

Product / Platform	Company	Market Status	Target / Mechanism of Action
Angio-Seal™ VIP	Terumo	Commercially available	Anchor + collagen plug “sandwich” seal at the femoral arteriotomy (bioabsorbable components).
FemoSeal™	Terumo	Commercially available	Dual bioabsorbable discs (inner + outer) mechanically seal the arteriotomy with suture/lock.
Perclose ProGlide™	Abbott	Commercially available	Suture-mediated closure (percutaneous suture delivery for CFA/CV access sites).
StarClose SE™	Abbott	Commercially available	Extravascular clip-based mechanical closure for common femoral artery access.
MANTA™	Teleflex	Commercially available	Large-bore biomechanical closure for femoral arterial access sites (14F/18F device sizes; indicated for large-bore use).
VASCADE® (arterial)	Haemonetics	Commercially available	Extravascular collagen patch + collapsible disc; leaves no permanent components.
MYNX CONTROL®	Cordis	Commercially available	Extravascular sealant (bioresorbable sealing approach for 5–7F femoral arterial access).
EXOSEAL™	Cordis	Commercially available	Extravascular bioabsorbable plug for femoral artery puncture site closure.
Celt ACD®	Vasorum	Commercially available	Implant-based mechanical closure for arterial puncture closure (small-bore femoral).
Boomerang™ Wire System	Cardiva Medical (now part of Haemonetics via acquisition)	FDA-cleared platform; historical commercial use	Temporary intraluminal disc/wire adjunct to support hemostasis with manual compression; removed after hemostasis.

 

Key Recent Developments by Companies in the Arteriotomy Closure Devices Market

Terumo:

• Puerto Rico capacity expansion to meet ANGIO-SEAL demand (USA)
  Terumo expanded manufacturing for its ANGIO-SEAL vascular closure device with a new 64,000-sq-ft build-out in Caguas (groundbreaking announced February 14, 2024) and later celebrated the facility’s official opening on August 20, 2025—signaling sustained demand for plug-based femoral arteriotomy closure in high-throughput cath and endovascular workflows.

• EU MDR certification secured for Angio-Seal VIP and FemoSeal (Europe)
  Terumo reported EU MDR certification for Angio-Seal VIP and FemoSeal, supporting continuity of commercial supply and labeling/IFU transition under MDR—an important “stay-in-market” milestone for femoral arterial closure platforms in Europe.

Vivasure Medical:

• PerQseal Elite receives CE Mark and prepares initial European rollout (Europe)
  Vivasure announced CE Mark approval for PerQseal Elite (April 22, 2025) and stated plans to launch in select European markets in summer 2025, adding momentum to fully bioresorbable, sutureless large-bore closure approaches used after procedures such as TAVR and EVAR.

• FDA PMA submission for arterial procedures following PATCH evidence (USA)
  Vivasure disclosed submission of a PMA application to the FDA for PerQseal Elite for arterial procedures (June 24, 2025), positioning the platform for potential U.S. entry in large-bore arteriotomy closure once reviewed.

Vasorum:

• FDA approval of Celt ACD PLUS with “Blood Signal” placement indicator (USA)
  Vasorum announced FDA approval of Celt ACD PLUS (March 2025), highlighting the next-generation design with a visual “blood signal” indicator and reporting initial commercial cases—supporting precision deployment for small-bore arterial closure in settings where ultrasound may not be available.

Cordis:

• Class II recall tied to MYNXGRIP carton labeling mix-up (USA)
  Cordis initiated a U.S. Class II recall posted January 5, 2024 for certain MYNXGRIP lots due to incorrect carton labeling (individual device labels noted as correct). Even when clinical risk is limited, these actions matter because arteriotomy closure outcomes are highly sensitive to correct device selection (e.g., sheath size compatibility).

Abbott:

• FDA-approved PMA supplements tied to Perclose ProGlide / Prostar XL sterilization-site updates (USA)
  FDA PMA supplement decisions in 2025 for Abbott’s suture-mediated closure family included sterilization-location changes/additions—moves that typically reflect manufacturing-network optimization and supply resilience for widely used femoral access closure systems.

Haemonetics:

• VASCADE portfolio commercialization expands in Europe (Europe)
  Haemonetics announced introduction of its VASCADE portfolio in Europe with initial commercial use in Germany and subsequent release in Italy—extending its collagen-patch-based approach for femoral arterial (and venous) closure into additional geographies.

Teleflex:

• continued clinical evidence base for MANTA large-bore closure (Global)
  Peer-reviewed clinical reporting in 2024 continued to evaluate outcomes with Teleflex’s MANTA in complex endovascular settings (large-bore access closure), reinforcing the competitive importance of large-bore arteriotomy closure performance as structural heart and aortic procedures scale.

 

Market Segmentation And Forecast Scope

The arteriotomy closure devices market is broadly segmented based on Product Type , Access Site , End User , and Geography . This segmentation helps delineate the strategic hotspots and investment-worthy segments that are influencing market momentum through 2030.

By Product Type

• Passive Closure Devices (collagen-based plugs, gel-based systems)

• Active Closure Devices (suture-mediated, clip-based)

• External Compression Devices

Passive closure devices accounted for approximately 43% of the global market share in 2024 , driven by their widespread use in both hospital and outpatient environments. These devices are favored due to their simplicity, lower procedural learning curve, and decreasing cost per unit.

However, active closure devices are expected to be the fastest-growing segment through 2030, thanks to their increasing adoption in complex vascular procedures and superior clinical outcomes in high-risk patient groups. Clinicians are shifting toward suture-mediated and clip-based systems for their precision, lower infection risk, and faster hemostasis , especially in high-volume cath labs.

 

By Access Site

• Femoral Artery Access

• Radial Artery Access

• Others (brachial, axillary)

While femoral artery access continues to dominate overall usage due to its compatibility with a wide range of interventional procedures, radial access closure devices are gaining traction — especially in North America and parts of Europe. This trend is fueled by growing physician preference for transradial interventions, which offer quicker patient recovery and lower complication rates.

 

By End User

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Cardiac Catheterization Laboratories

• Specialty Clinics

Hospitals remain the largest adopters, attributed to their procedural volume and capacity to handle high-risk vascular interventions. That said, ambulatory surgical centers and outpatient catheterization labs are emerging as lucrative sub-segments, particularly in developed markets where cost containment and same-day discharge models are prioritized.

 

By Region

• North America

• Europe

• Asia Pacific

• LAMEA (Latin America, Middle East & Africa)

Each region exhibits a distinct pattern of clinical adoption, regulatory oversight, and healthcare infrastructure maturity — elements that significantly influence the uptake of arteriotomy closure devices.

Inferred forecast: Between 2024 and 2030, Asia Pacific is poised to be the fastest-growing regional market, led by rising cardiovascular procedure rates, healthcare investments, and rapid technology diffusion in nations like China and India.

This multi-dimensional segmentation underscores the market’s evolution toward precision-based, user-specific closure solutions that align with clinical and economic outcomes.

 

Market Trends And Innovation Landscape

The arteriotomy closure devices market is undergoing a transformation, driven by a convergence of biomedical engineering, regulatory modernization, and precision interventional care . Innovation is not limited to product refinement but extends into how closure solutions integrate with overall procedure pathways — from arterial access to post-operative mobility.

1. Material Science Advancements A major trend involves the development of bioabsorbable materials and non-thrombogenic coatings that enhance vascular compatibility. Leading manufacturers are investing in collagen-derived plugs, polyethylene glycol (PEG)-based gels, and fast-resorbing polymers , which reduce inflammation and accelerate healing.

An emerging R&D priority is the formulation of composite biomaterials that offer both mechanical strength and controlled degradation — allowing faster hemostasis with minimal arterial trauma.

 

2. Rise of Active Closure Technologies Active closure systems — particularly suture-mediated and clip-based platforms — are advancing rapidly. These devices offer superior efficacy in obese, anticoagulated, or high-risk patients, where passive methods may be less effective.

Recent prototypes feature multi-point anchoring and pressure sensors to ensure precise placement and tension calibration. Some systems are also being integrated with imaging feedback for real-time deployment.

 

3. Integration with Digital Health and Remote Monitoring Though nascent, digital tracking solutions are being explored to monitor post-closure complications like bleeding or thrombosis. Startups are working on wearable patches that can track temperature, local pressure, and bio-signals post-ACD deployment.

This convergence of closure devices and digital monitoring opens up new value-based care models, especially in outpatient settings.

 

R&D and Pipeline Activity

• OEMs are accelerating pipeline expansion into hybrid closure systems that combine mechanical and biological methods — aiming to enhance versatility and reduce skill dependency.

• Academic collaborations are also on the rise. Notably, university hospitals in Japan and Germany are testing next-gen, sutureless biodegradable devices in pilot trials.

• Some manufacturers are investing in smaller-diameter systems optimized for radial access and pediatric use — a previously underserved niche.

 

Strategic Partnerships and M&A

Several recent mergers and alliances indicate a trend toward portfolio diversification and geographic expansion:

• Partnerships between vascular access device companies and AI-based imaging firms are helping in developing integrated closure and diagnostic platforms.

• Strategic acquisitions of startup innovators by larger players are enabling rapid commercialization of niche technologies like robotic-assisted closure and bioengineered scaffolds .

According to industry insiders, this wave of integration will redefine closure devices not just as an endpoint, but as a continuum of vascular intervention — influencing how entire procedures are planned and reimbursed.

Innovation in this sector is not just about speed or safety — it's about creating procedural value chains that enhance recovery, reduce downstream complications, and align with hospital KPIs.

 

Competitive Intelligence And Benchmarking

The arteriotomy closure devices market is moderately consolidated, with a mix of established giants and emerging innovators competing on technology, geographic reach, and procedural outcomes. Companies are aligning their strategies with the ongoing shift toward outpatient care, minimally invasive techniques, and value-based purchasing models.

Key Players and Strategic Profiles:

Abbott Laboratories
A dominant global player, Abbott has maintained leadership through its diversified vascular closure portfolio, especially in suture-mediated systems . It leverages a strong distribution network and invests significantly in clinical validation studies to support reimbursement claims. The company also benefits from synergies with its broader cardiovascular device ecosystem.

 

Terumo Corporation
Terumo has carved a niche in radial closure devices and continues to gain ground in femoral applications. Known for innovation and reliability, the company emphasizes procedure-specific devices that optimize workflow efficiency. Terumo’s R&D centers in Japan and the U.S. are driving development of ultra-minimally invasive platforms.

 

Cardinal Health
Cardinal Health is a key player in passive closure solutions , offering plug-based systems that are widely adopted in hospitals and surgical centers . The company focuses on scalability and affordability, targeting both high-volume institutions and emerging markets. Strategic acquisitions have helped it strengthen its vascular access portfolio.

 

Morris Innovative
This U.S.-based player is known for its bioabsorbable closure technologies , especially in hybrid devices. It has partnered with academic institutions for product testing and aims to penetrate the ambulatory surgical center segment with user-friendly, preloaded systems. Experts note that Morris’s agility allows it to commercialize innovations faster than larger competitors.

 

Medtronic
Though not traditionally dominant in this niche, Medtronic has expanded its footprint via integration with its broader cardiovascular solutions. Its strategy includes vertical bundling — offering closure devices alongside diagnostic catheters and interventional tools to streamline procurement for hospital systems.

 

Vascular Solutions (a subsidiary of Teleflex)
A growing force in femoral access, Vascular Solutions benefits from Teleflex’s strong hospital relationships and cross-selling ability . Its devices are known for ergonomic designs and procedural safety. The company is actively developing next-gen plug materials with improved resorption profiles.

 

Essential Medical, Inc.
A nimble innovator, Essential Medical focuses on femoral closure for large-bore applications. It gained attention for introducing devices suitable for TAVR and EVAR procedures , where conventional closures often underperform. Its technology is particularly favored in complex cardiology units in North America and Europe.

 

Competitive Strategies Snapshot

Company	Strategy Focus	Innovation Level	Geographic Reach	Key Differentiator
Abbott	Clinical evidence, product diversity	High	Global	Trusted suture-mediated systems
Terumo	Radial specialization	Moderate–High	APAC & EU-centric	Procedural integration
Cardinal Health	Cost-effective scale	Moderate	North America	Passive plug systems
Morris Innovative	Rapid prototyping	High	U.S.-centric	Hybrid bioabsorbables
Medtronic	System integration	Moderate	Global	End-to-end vascular tools
Vascular Solutions	Hospital alignment	Moderate	U.S. & EU	Device ergonomics
Essential Medical	Niche targeting	High	U.S. & selective EU	Large-bore closure efficacy

As outpatient vascular care expands, competition is shifting from traditional volume-based pricing to performance-driven procurement — where device versatility, recovery speed, and procedural compatibility will dictate market share.

 

Regional Landscape And Adoption Outlook

The arteriotomy closure devices market exhibits marked regional disparities in terms of procedure volumes, technology adoption, reimbursement structures, and regulatory pathways. Each geography reflects a distinct healthcare strategy — from innovation hubs to cost-sensitive mass markets.

North America

North America accounted for the largest market share in 2024 , driven by high cardiovascular procedure volumes, favorable reimbursement policies, and the early adoption of advanced closure systems.

• The United States is the global frontrunner in ACD utilization. Its extensive network of catheterization labs, combined with a strong outpatient infrastructure, supports high device turnover.

• CMS ( Centers for Medicare & Medicaid Services) reimbursement for same-day discharge and ambulatory cardiovascular procedures has further catalyzed demand for efficient closure devices.

• The market is innovation-driven, with continuous clinical validation and training programs supporting the rollout of suture-based and hybrid systems .

Major U.S. hospital networks prefer vendors offering bundled procedural solutions, creating opportunities for companies that integrate closure devices into their broader vascular portfolios.

 

Europe

Europe follows closely behind, with adoption anchored in procedural safety and clinical governance.

• Countries like Germany, France, and the UK are leading adopters, with widespread use of both passive and active closure systems.

• The EU MDR (Medical Device Regulation) has increased scrutiny on device efficacy and traceability, prompting regional players to focus on post-market surveillance and clinician training.

• Preference leans toward evidence-backed devices , especially in academic hospitals and public health networks.

While Europe is slower than North America in switching from femoral to radial access, the trend is accelerating in tertiary centers — pushing demand for radial-specific closure tools .

 

Asia Pacific

Asia Pacific is poised to be the fastest-growing region from 2024 to 2030. This growth is underpinned by:

• A surge in interventional cardiology and peripheral procedures across China, India, Japan, and South Korea .

• Rapid expansion of healthcare infrastructure, especially urban cath labs and ambulatory centers .

• Increased government focus on non-communicable disease management and cardiovascular screening.

Although current per capita usage of ACDs is lower than in Western markets, volume scalability and tech democratization are turning Asia into a hotbed for mid-cost, high-efficiency devices.

For example, in South Korea, leading hospitals have begun deploying hybrid closure systems for high-throughput catheter-based therapies — with local startups collaborating on material innovation and custom fit designs.

 

LAMEA (Latin America, Middle East, and Africa)

This region presents high white-space opportunity despite a slower uptake:

• Brazil, Saudi Arabia, and the UAE are the strongest adopters, supported by private hospital chains and expanding tertiary care infrastructure.

• Regulatory pathways are improving, but device accessibility and price sensitivity remain barriers in lower-income nations.

• Increasing demand for point-of-care and mobile intervention units — particularly in rural regions — is fueling interest in easy-to-use passive devices .

Multinational players are targeting LAMEA through distributor partnerships and cost-reduction strategies , aiming to address the unmet need while complying with region-specific procurement norms.

Regional success in the arteriotomy closure devices market hinges not just on product superiority, but on alignment with procedural culture, clinical training, and health system economics.

 

End-User Dynamics And Use Case

The use of arteriotomy closure devices (ACDs) varies significantly across healthcare settings, influenced by procedural complexity, reimbursement pressure, and post-operative care goals. Understanding these dynamics is essential for device manufacturers aiming to customize offerings and education strategies across clinical environments.

1. Hospitals

Hospitals — particularly tertiary and quaternary care centers — account for the largest share of ACD consumption . Their high procedural volumes, broad case mix (including high-risk vascular access), and multidisciplinary teams make them ideal users of both active and passive systems .

• Suture-mediated devices are often preferred in hospitals due to their precision and applicability in complex anatomies.

• Integration of closure solutions with imaging guidance and vascular access kits is common to support procedural speed and consistency.

Hospital procurement decisions are heavily influenced by clinical evidence, device versatility , and bundled pricing with other vascular tools .

 

2. Ambulatory Surgical Centers (ASCs)

ASCs are emerging as high-growth end users , especially in North America and Europe. With a rising shift toward same-day discharge for diagnostic and therapeutic angiograms , ASCs rely on closure devices to:

• Reduce manual compression time

• Shorten post-op recovery

• Enable rapid turnover of procedure rooms

These facilities often favor plug-based passive systems that require minimal training and offer quick deployment. Cost efficiency and low complication rates are essential drivers in this segment.

 

3. Cardiac Catheterization Laboratories

Standalone or hospital-integrated cath labs form a specialized user group where closure devices are deeply embedded in procedural protocols.

• High-frequency users of radial and femoral closure tools

• Use is governed by interventionalist preference , which can vary significantly by training and familiarity

• Labs typically require customizable solutions to suit sheath sizes and access sites

As outpatient cardiology expands, many cath labs are also transitioning to outpatient models, intensifying their reliance on fast-acting, reliable closure mechanisms.

 

4. Specialty Clinics and Vascular Access Centers

These niche users are gaining importance in mature healthcare markets. With growing attention to preventive vascular care and AV access interventions , these centers require:

• Devices suitable for both arterial and venous access

• Smaller-profile systems that reduce trauma

• Solutions optimized for patients on anticoagulation

 

Use Case Scenario

A tertiary hospital in South Korea conducted a pilot program to transition 60% of its diagnostic angiography cases to same-day discharge protocols. By incorporating suture-based arteriotomy closure devices in combination with mobile recovery monitoring, the average bed occupancy time dropped by 40%. Patient satisfaction scores improved due to quicker ambulation, and the hospital reported a 25% increase in procedural throughput over six months. The success prompted procurement of hybrid closure systems for high-risk and obese patients to further scale the model.

The procedural value of ACDs now goes beyond hemostasis — they are a cornerstone of modern, efficient vascular care models tailored for speed, safety, and sustainability.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

The arteriotomy closure devices space has seen a string of noteworthy activities that signal strategic pivots toward innovation, scale, and broader market accessibility:

• Abbott Laboratories received expanded CE mark approval for its next-generation vascular closure system, designed to reduce deployment time by 35% compared to previous models.

• Terumo Corporation launched a radial access closure device in Europe, tailored for small-diameter arteries and same-day discharge environments.

• Essential Medical, Inc. announced successful outcomes from a multicenter study evaluating its large-bore femoral closure device for TAVR applications, showing a 96% success rate with no major vascular complications.

• Teleflex completed the acquisition of a vascular access device startup, enhancing its IP portfolio around clip-based closure systems for outpatient settings.

• A German research consortium initiated clinical trials for a bioabsorbable, ultrasound-guided closure system designed to self-adjust tension during healing.

 

Opportunities

• Outpatient & Same-Day Discharge Models: As payers and providers shift toward value-based care , there is immense opportunity for ACDs to become standard tools for enabling same-day procedures , reducing inpatient costs, and improving operational flow.

• Emerging Market Penetration: Rapid procedural volume growth in India, China, Brazil, and GCC countries offers a fertile ground for mid-cost, simplified closure systems , especially those requiring minimal training.

• Integration with Imaging and Robotics: The integration of closure devices with intraoperative imaging, robotic navigation, and smart sensors could unlock new use cases in high-risk and hybrid operating rooms.

 

Restraints

• Regulatory Delays & Post-Market Surveillance Requirements: The introduction of stricter device validation norms, particularly in Europe (EU MDR) and Japan , is increasing the cost and time-to-market for new innovations — slowing adoption cycles.

• High Upfront Device Costs in Cost-Sensitive Markets: In regions with limited reimbursement frameworks or budget constraints, manual compression remains the default standard , restraining the commercial adoption of advanced ACDs.

As manufacturers pursue automation and precision, balancing regulatory compliance, clinician usability, and pricing strategy will be the next competitive frontier.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.21 Billion
Revenue Forecast in 2030	USD 1.86 Billion
Overall Growth Rate	CAGR of 7.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Access Site, By End User, By Geography
By Product Type	Passive Closure Devices, Active Closure Devices, External Compression Devices
By Access Site	Femoral, Radial, Others
By End User	Hospitals, ASCs, Cath Labs, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Shift to outpatient vascular care - Material science and bioabsorbable innovation - Increasing catheter-based procedures
Customization Option	Available upon request